Navigation Links
Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
Date:5/13/2009

SOUTH SAN FRANCISCO, Calif., May 13 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the Leerink Swann Oncology Roundtable Conference on Wednesday, May 20, at 2:00 p.m. Eastern Time in New York.

Dr. McMahon's corporate presentation will include a discussion about the clinical development program for the Company's lead product candidate, picoplatin. In addition, Dr. McMahon will participate in an expert panel discussion on the same day at 8:10 a.m. Eastern Time entitled "New Developments in Solid Tumors, Focusing on GU and GI Cancers."

A live audio webcast of the corporate overview will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
2. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
4. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
5. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
6. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
7. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
10. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
11. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... NY (PRWEB) , ... June 14, 2017 , ... ... bushing materials for pumps and process equipment, has appointed Andrew Ondish as ... York. , Ondish holds a B.S. degree in Petroleum Engineering from Colorado School ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... and personalized medicine technology, today announced four new distribution agreements for Cynvenio’s ClearID line ... cancer care cycle. The commercial agreements will make ClearID available immediately in Israel, ...
(Date:6/14/2017)... Alberta , June 14, 2017   ... Systems (MEMS) and a primary supplier of sensors, ... in Placentia, California to ... Silicon Via,s (TSV).  The joint development of this ... to enable a truly flexible and cost effective ...
(Date:6/14/2017)... ... June 13, 2017 , ... ... an organism on a molecular level that is closely associated with clinical ... bottlenecks to biomarker discovery in clinical-based metabolomics research. , An introduction to ...
Breaking Biology Technology:
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
Breaking Biology News(10 mins):